2000
DOI: 10.1001/archderm.136.3.374
|View full text |Cite
|
Sign up to set email alerts
|

Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma

Abstract: Background : We report the use of a new treatment modality in 2 patients with primary cutaneous B-cell lymphoma. In a 58-year-old woman with progressive nodular lesions on the scalp and face, several treatment attempts either failed or could not be used because of severe adverse effects and underlying epilepsy. The patient declined radiotherapy. A 30-year-old man presented with recurrence of tumor nodules occipitally, thoracically, on the arm, and on the right thigh after several excisions.Observations: Intra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
64
0
5

Year Published

2000
2000
2015
2015

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 89 publications
(72 citation statements)
references
References 15 publications
3
64
0
5
Order By: Relevance
“…In addition, comparison between systemic and intralesional treatment with rituximab in PCFCL could be of interest because also in patients treated intralesionally a complete disappearance of B cells in the peripheral blood has been noted, indicating a systemic effect. 34,65 In selected cases, intralesional rituximab might prove to be an equally effective, but much cheaper, alternative for systemic rituximab. Cutaneous lymphoma groups with experience in treating B burgdorferi-associated PCMZL with (systemic) antibiotics are encouraged to publish their treatment results, either positive or negative, to find out whether further studies are required.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, comparison between systemic and intralesional treatment with rituximab in PCFCL could be of interest because also in patients treated intralesionally a complete disappearance of B cells in the peripheral blood has been noted, indicating a systemic effect. 34,65 In selected cases, intralesional rituximab might prove to be an equally effective, but much cheaper, alternative for systemic rituximab. Cutaneous lymphoma groups with experience in treating B burgdorferi-associated PCMZL with (systemic) antibiotics are encouraged to publish their treatment results, either positive or negative, to find out whether further studies are required.…”
Section: Discussionmentioning
confidence: 99%
“…Ten of 12 patients treated intralesionally reached CR, and the other 2 patients had a partial remission. 34,36,[65][66][67] Dosages and treatment regimens varied between 10 and 30 mg per lesion per application for 2 or 3 times a week. Duration of treatment was more variable, ranging from one or 2 injections in total, to treatment for up to 6 months.…”
Section: Rituximab Intralesional and Intravenousmentioning
confidence: 99%
“…[375][376][377] Rituximab has been effective as a first-line treatment option for patients with indolent CBCLs with multiple lesions for which local therapy is not effective. [378][379][380][381][382] In a series of 16 patients with PCBCL, 14 patients (87.5%) experienced complete remission, with 35% of these patients experiencing relapse between 6 and 37 months. 382 In another retrospective analysis of 15 patients with indolent CBCLs, the overall objective response rate was 87% (60% with a complete response, 27% with a partial response) with a median follow-up of 36 months.…”
Section: Nccn Recommendationsmentioning
confidence: 99%
“…Heinzerling ve ark ise primer kutanöz B hücreli lenfoma olgusunda intralezyonel rituksimabı başarılı şekilde kullanmışlardır. Yine Heinzerling ve ark rituksimabla tedavi ettikleri 10 primer kutanöz B hü-celi lenfoma olgusundan 6 tanesinde tedavi başarısızlığı gözlemişlerdir (26,37). Paul ve ark ise intralezyonel rituksimabın kutanöz B hücreli lenfomalarda lezyon başına 10-30 mg dozda toplam 350 mg 3-5 hafta boyunca haftada 2-3 kez uygulandı-ğında güvenli ve etkili olarak uygulanabileceğini ileri sürmüştür.…”
Section: A-primer Kutanöz B Hücreli Lenfoma Ve Diğer Lenfomalarunclassified